// App-Quantinova.ai

PD1-07 : Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130

Researchers

Presenter

  • Hope Rugo

Principal Investigators

  • Sherene Loi

  • Sylvia Adams

  • Peter Schmid

  • Andreas Schneeweiss

  • Carlos H Barrios

  • Hiroji Iwata

  • Vronique Diras

  • Eric P Winer

  • Mark M Kockx

  • Dieter Peeters

  • Stephen Y Chui

  • Jennifer C Lin

  • Anh Nguyen Duc

  • Guiseppe Viale

  • Luciana Molinero

  • Leisha A Emens

Medical Centers

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • NYU Langone Medical Center, New York, NY

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany

  • Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Departments of Medical Oncology and Radiotherapy, Centre Eugene Marquis, Rennes, France

  • Dana-Farber Cancer Institute, Boston, MA

  • HistoGeneX, Antwerp, Belgium

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • University of Milano-Bicocca and European Institute of Oncology, Milano, Italy

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

Locations

  • United States

  • Australia

  • United Kingdom

  • Germany

  • Brazil

  • Japan

  • France

  • Belgium

  • Switzerland

  • Italy

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • SP263

Outcome

  • N/A


Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02425891

Sponsors

  • N/A

Result

  • N/A